top of page

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Clinicaltrials.gov ID

NCT04644068

Status

Recruiting

Study Type

Interventional, Phase 1/2

Sponsor

AstraZeneca

Start Date

November 12, 2020

Anticipated End Date

December 15, 2026

Study Contact

Name: AstraZeneca Clinical Study Information Center

Phone Number:1-877-240-9479

Email: information.center@astrazeneca.com

About the Study

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Conditions

  • Ovarian Cancer

  • Breast Cancer

  • Pancreatic Cancer

  • Prostate Cancer

    Additional Indications Below for Module 4 and 5

  • Non-small Cell Lung Cancer

  • Colorectal Cancer

  • Bladder Cancer

  • Gastric Cancer

  • Biliary Cancer

  • Cervical Cancer

  • Endometrial Cancer

  • DRUG: AZD5305|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: T- Dxd|DRUG: Dato-DXd|DRUG: Camizestrant

    Small Cell Lung Cancer Only in Module 5


Inclusion/Exclusion Criteria?

Primary, Secondary, Other Outcome Measures??

Locations in Canada

  • Kelowna General Hospital, Kelowna, British Columbia, V1Y 5L3, Canada

  • Vancouver General Hospital, Vancouver, British Columbia, V5Z 1K1, Canada

  • London Health Sciences Centre, London, Ontario, N6A 4L6, Canada

  • Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada

  • Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada

  • CHUM, Montréal, Québec, H2X 0A9, Canada

  • Jewish General Hospital, Montréal, Québec, H3T 1E2, Canada

  • Hôtel-Dieu de Québec, Québec, G1R 2J6, Canada

Apply Now

About the Study

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Conditions

  • Ovarian Cancer

  • Breast Cancer

  • Pancreatic Cancer

  • Prostate Cancer

    Additional Indications Below for Module 4 and 5

  • Non-small Cell Lung Cancer

  • Colorectal Cancer

  • Bladder Cancer

  • Gastric Cancer

  • Biliary Cancer

  • Cervical Cancer

  • Endometrial Cancer

  • DRUG: AZD5305|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: T- Dxd|DRUG: Dato-DXd|DRUG: Camizestrant

    Small Cell Lung Cancer Only in Module 5


Interventions